On the other hand, although the treatment options for DKD include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRAs), their efficacy is still limited [4]. The gene discussed is NR3C2; the disease is diabetic kidney disease.